



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/072,159	
			Filing Date	February 5, 2002	
			First Named Inventor	Bernard Bihain	
			Art Unit	1646	
			Examiner Name		
Sheet	1	of	6	Attorney Docket Number	G-029US04DIV

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-			
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document /Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
SC	F1	WO 97/27286 A1	07-31-1997	Progenitor, Inc.	All	
SC	F2	WO98/01257 A2	01-15-1998	H. Federhenn	All	
SC	F3	WO 98/20165 A2	05-14-1998	Whitehead Institute for Biomedical Research	All	
	F4					
	F5					
	F6					
	F7					

Examiner Signature	<i>Egon Ueber</i>	Date Considered	10/20/05
--------------------	-------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete If Known</b>			
		Application Number	10/072,159		
		Filing Date	February 5, 2002		
		First Named Inventor	Bernard Bihain		
		Group Art Unit	1646		
		Examiner Name			
Sheet	2	of	6	Attorney Docket Number	G-029US04DIV

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
H	R1	AUSTIN, et al. "Hypertriglyceridemia as a Cardiovascular Risk Factor," <i>Am. J. Cardiol.</i> (1998), Volume 81, pages 7B-12B.	
	R2	BALDO, et al. "The Adipsin-Acylation Stimulating Protein System and Regulation of Intracellular Triglyceride Synthesis," <i>J. Clin. Invest.</i> (1993), Volume 92, pages 1543-1547.	
	R3	BARTLES, J.R., et al. "Biogenesis of the Rat Hepatocyte Plasma Membrane," <i>Methods Enzymol.</i> (1990), Volume 191, pages 825-841.	
	R4	BIHAIN, et al. "Free Fatty Acids Activate a High Affinity Saturable Pathway for Degradation of Low-Density Lipoproteins in Fibroblasts from a Subject Homozygous for Familial Hypercholesterolemia," <i>Biochemistry</i> (1992), Volume 31, number 19, pages 4628-4636.	
	R5	BRENDEL, V. et al. "Methods and algorithms for statistical analysis of protein sequences," <i>Proc. Natl. Acad. Sci. USA</i> (1992), Volume 89, pages 2002-2006.	
	R6	CHEN, W.J. et al. "NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low density lipoprotein receptor," <i>J. Biol. Chem.</i> (1990), Volume 265, pages 3116-3123.	
	R7	COLE-STRAUSS et al. "Correction of the Mutation Responsible for Sickle Cell Anemia by an RNA-DNA Oligonucleotide," <i>Science</i> (1996), Volume 273, pages 1386-1389.	
	R8	DAVIS, C.G. et al. "The J.D. Mutation in Familial Hypercholesterolemia: Amino Acid Substitution in Cytoplasmic Domain Impedes Internalization of LDL Receptors," <i>Cell</i> (1986), Volume 45, pages 15-24.	
	R9	DIETRICH, J. et al. "CD3γ Contains a Phosphoserine-Dependent Di-Leucine Motif Involved in Down-Regulation of the T Cell Receptor," <i>EMBO Journal</i> (1994), Volume 13, pages 2156-2166.	
	R10	EVERHART, J.E. "Weight Change and Obesity After Liver Transplantation: Incidence and Risk Factors," <i>Liver Transpl. Surg.</i> (1998), Volume 4, pages 285-296.	
	R11	FEEMAN, JR., W.E. "Hypertriglyceridemia and Atherosclerosis," <i>Annals of Internal Med.</i> (1998), Volume 128, number 1, pages 73-74.	
	R12	GOLDSTEIN, J.L., et al. "Familial Hypercholesterolemia," in <i>The Metabolic and Molecular Bases of Inherited Disease</i> (Volume II, 7 <sup>th</sup> ed., Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, B. editors, 1995), pages 1981-2030; McGraw-Hill; New York, New York, USA.	
H	R13	GOLDSTEIN, et al. "Hyperlipidemia in Coronary Heart Disease," <i>J. Clin. Invest.</i> (1973), Volume 52, pages 1533-1543.	

Examiner Signature	<i>Hyman Chur</i>	Date Considered	10/20/05
--------------------	-------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/072,159		
		Filing Date	February 5, 2002		
		First Named Inventor	Bernard Bihain		
		Group Art Unit	1646		
		Examiner Name			
Sheet	3	of	6	Attorney Docket Number	G-029US04DIV

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
H	R14	GURA, et al. "Obesity Sheds Its Secrets," <i>Science</i> (1997), Volume 275, pages 751-753.	
	R15	HERZ, J., et al. "Surface Location and High Affinity for Calcium of a 500-kd liver Membrane Protein Closely Related to the LDL-receptor Suggest a Physiological Role as Lipoprotein Receptor," <i>European Molecular Biology Laboratory</i> (1988), Volume 7, pages 4119-4127.	
	R16	HONORE, B., et al. "Cloning and Expression of a cDNA Covering the Complete Coding Region of the P32 subunit of Human pre-mRNA Splicing Factor SF2," <i>Gene</i> (1993), Volume 134, pages 283-287.	
	R17	HU, E., et al. "AdipoQ is a Novel Adipose-specific Gene Dysregulated in Obesity," <i>J. Biol. Chem.</i> (1996), Volume 271, number 18, pages 10697-10703.	
	R18	HUETTINGER, M., et al. "Characteristics of Chylomicron Remnant Uptake into Rat Liver," <i>Clin. Biochem.</i> (1988), Volume 21, pages 87-92.	
	R19	KARPE, F., et al. "Clearance of Lipoprotein Remnant Particles in Adipose Tissue and Muscle in Humans," <i>J. Lipid. Res.</i> (1997), Volume 38, pages 2335-2343.	
	R20	KARPE, F., et al. "Magnitude of Ailimentary Lipemia is Related to Intima-media Thickness of the Common Carotid Artery in Middle-aged Men," <i>Elsevier Science Ireland</i> (1998), Volume 141, pages 307-314.	
	R21	KHALLOU, et al. "Correction of delayed postprandial plasma lipid response in genetically obese mice by injection of recombinant leptin": Abstract from the 69 <sup>th</sup> Scientific Sessions, New Orleans, LA: Supplemental to Circulation, American Heart Assoc., (1996), Vol. 94:8.	
	R22	KRAINER, A.R., et al. "Functional Expression of Cloned Human Splicing Factor SF2: Homology to RNA-Binding Proteins, U1 70K, and Drosophila Splicing Regulators," <i>Cell</i> (1991), Volume 66, pages 383-394.	
	R23	LEE, M. G-S., et al. "Characterization of a cDNA Encoding a Cysteine-Rich Cell Surface Protein Located in the Flagellar Pocket of the Protozoan <i>Trypanosoma brucei</i> ," <i>Molec. Cell. Biol.</i> (1990), Volume 10, pages 4506-4517.	
	R24	LETOURNEUR, F., et al. "A Novel Di-Leucine Motif and a Tyrosine-Based Motif Independently Mediate Lysosomal Targeting and Endocytosis of CD3 Chains," <i>Cell</i> (1992), Volume 69, pages 1143-1157.	
	R25	LEWIS, G.F., et al. "Postprandial Lipoprotein Metabolism in Normal and Obese Subjects: Comparison after the Vitamin A Fat-Loading Test," <i>J. of Clinic. Endo.</i> (1990), Volume 71, pages 1041-1050.	
H	R26	LIN, et al. "Archaic Structure of the Gene Encoding Transcription Factor USF," <i>Journal of Biological Chemistry</i> (1994), Volume 269, number 19, pages 23894-28903.	

Examiner Signature	<i>Gyan Chit</i>	Date Considered	10/20/05
--------------------	------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/072,159
(use as many sheets as necessary)		Filing Date	February 5, 2002
		First Named Inventor	Bernard Bihain
		Group Art Unit	1646
		Examiner Name	
Sheet	4	of	6
		Attorney Docket Number	G-029US04DIV

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LA	R27	LIU, Q., et al. "Design of Polydactyl Zinc-finger Proteins for Unique Addressing within Complex Genomes," <i>Proc. Natl. Acad. Sci. USA</i> (1997), Volume 94, pages 5525-5530.	
	R28	MAHLEY, R.W., et al. "Type III Hyperlipoproteinemia (Dysbetalipoproteinemia): The Role of Apolipoprotein E in Normal and Abnormal Lipoprotein Metabolism," in <i>The Molecular Basis of Inherited Disease</i> (1995), pages 1953-1980; Scriver CR, Beaudet, A.L., Sly, W.S., Valle, D., editors; McGraw-Hill; New York.	
	R29	MANN, et al. "Mechanism of Activation and Functional Significance of the Lipolysis-Stimulated-Receptor. Evidence for Role as Chylomicron Remnant Receptor," <i>Biochemistry</i> (1995), Volume 34, number 33, pages 10421-10431.	
	R30	MASSIE, et al. "Inducible Overexpression of a Toxic Protein by an Adenovirus Vector with a Tetracycline-Regulatable Expression Cassette," <i>Journal of Virology</i> (1998), Volume 72, pages 2289-2296.	
	R31	MONTAGUE, et al. "Congenial Leptin Deficiency is Associated with Severe Early-onset Obesity in Humans," <i>Nature</i> (1997), Volume 387, pages 903-908.	
	R32	PARRA-LOPEZ, C.A., et al. "Presentation on Class II MHC Molecules of Endogenous Lysozyme Targeted to the Endocytic Pathway," <i>J. Immunol.</i> (1997), Volume 158, pages 2670-2679.	
	R33	PENGUE, G., et al. "Repression of Transcriptional Activity at a Distance by the Evolutionary Conserved KRAB Domain Present in a Subfamily of Zinc Finger Proteins," <i>Nucleic Acids Research</i> (1994), Volume 22, number 15, pages 2908-2914.	
	R34	RAJPUT-WILLIAMS, J., et al. "Variation of Apolipoprotein-B Gene is Associated with Obesity, High Blood Cholesterol Levels, and Increased Risk of Coronary Heart Disease," <i>The Lancet</i> (1988), pages 1442-1446.	
	R35	RUTHERFORD, S., et al. "Association of a Low Density Lipoprotein Receptor Micro-satellite Variant with Obesity," <i>Int. J. of Obesity</i> (1997), Volume 21, pages 1032-1037.	
	R36	SCHAFFLER, et al. "Identification and Characterization of the Human Adipocyte apM-1 Promoter," <i>Biochem. and Biophys. Res. Comm.</i> (1998), Volume 1399, pages 187-189.	
	R37	SCHERER, et al. "A novel Serum Protein Similar to C1q, Produced Exclusively in Adipocytes," <i>J. Biol. Chem.</i> (1995), Volume 270, pages 26746-26749.	
	R38	SHIMABUKURO, M., et al. "Direct Antidiabetic Effect of Leptin Through Triglyceride Depletion of Tissues," <i>Proc. Natl. Acad. Sci. USA</i> (1997), Volume 94, pages 4637-4641.	
LC	R39	SHIMANO, H., et al. "Overproduction of Cholesterol and Fatty Acids Causes Massive Liver Enlargement in Transgenic Mice Expression Truncated SREBP-1a," <i>J. Clin. Invest.</i> (1996), Volume 98, pages 1575-1584.	

Examiner Signature		Date Considered	10/20/05
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/072,159
				Filing Date	February 5, 2002
				First Named Inventor	Bernard Bihain
				Group Art Unit	1646
				Examiner Name	
				Attorney Docket Number	G-029US04DIV
Sheet	5	of	6		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SK	R40	SHIN, J., et al. "Phosphorylation-dependent Down-modulation of CD4 Requires a Specific Structure within the Cytoplasmic Domain of CD4," <i>J. of Biol. Chem.</i> (1991), Volume 266, pages 10658-10665.	
	R41	SIMOS, G., et al. "The lamin B Receptor-associated Protein p34 Shares Sequence Homology and Antigenetic Determinants with the Splicing Factor 2-associated with Protein p32," <i>FEBS Letters</i> (1994), Volume 346, pages 225-228.	
	R42	STEINGRIMSSON, et al. "Murine Chromosomal Location of Five BHLH-Zip Transcription Factor Genes," <i>Genomics</i> (1995), Volume 28, pages 179-183.	
	R43	YAN DEN BERG, R.H., et al. "Intracellular Localization of the Human Receptor for the Globular Domains of C1q," <i>American Association of Immunologists</i> (1997), Volume 158, pages 3909-3916.	
	R44	VERHEY, K.J., et al. "A Leu-Leu Sequence is Essential for COOH-terminal Targeting Signal of GLUT4 Glucose Transporter in Fibroblasts," <i>J. Biol. Chem.</i> (1994), Volume 269, pages 2353-2356.	
	R45	WANG, et al. "Upstream Stimulatory Factor Binding to the E-box at -65 is required for Insulin Regulation of the Fatty Acid Synthase Promoter," <i>J. Biol. Chem.</i> (1997), Volume 272, pages 26367-26374.	
	R46	YEN, et al. "Identification of a Lipolysis-Stimulated Receptor That is Distinct from the LDL Receptor and the LDL Receptor Related Protein," <i>Biochemistry</i> (1994), Volume 33, number 5, pages 1172-1180.	
	R47	ZHANG, M., et al. "Tumor Necrosis Factor," in <i>The Cytokine Handbook</i> (3 <sup>rd</sup> ed., 1998), pages 517-548.	
	R48	ZHONG, G., et al. "Related Leucine-based Cytoplasmic Targeting Signals in Invariant Chain and Major Histocompatibility Complex Class II Molecules Control Endocytic Presentation of Distinct Determinants in a Single Protein," <i>J. Exp. Med.</i> (1997), Volume 185, pages 429-438.	
	R49	GROENEN, P. et al., "STRUCTURE, SEQUENCE AND CHROMOSOME 19 LOCATION OF HUMAN USF2...", EMBL Sequence Database, January 24, 1997, XP002067467.	
	R50	LAMERDIN, J.E., "HOMO SAPIENS DNA FROM CHROMOSOME 19-COSMID R30879 CONTAINING USF2, GENOMIC SEQUENCE, EMBL Sequence Database, March 26, 1997, XP002096567.	
SK	R51	LAMERDIN, J.E., et al., "SEQUENCE ANALYSIS OF A 1 MB REGION OF HUMAN 19Q13.1", EMBL Sequence Database, May 28, 1997, XP002096568.	

Examiner Signature	<i>Lyman Chiu</i>	Date Considered	10/20/05
--------------------	-------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/072,159
				Filing Date	February 5, 2002
				First Named Inventor	Bernard Bihain
				Group Art Unit	1646
				Examiner Name	
				Attorney Docket Number	G-029US04DIV
Sheet	6	of	6		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JS	R52	LAMERDIN, J.E., et al. "HUMAN LISCH7", EMBL Sequence Database, July 1, 1997, XP002096569.	
	R53	LAMERDIN, J.E., et al. "LIVER-SPECIFIC BHLF-ZIP TRANSCRIPTION FACTOR, LISCH7", EMBL Sequence Database, July 1, 1997, XP002096570.	
	R54	LIN, Q., et al., "LISCH7, A LIVER SPECIFIC GENE IMMEDIATELY UPSTREAM OF THE USF2 GENE ON CHROMOSOME 7", EMBL Sequence Database, May 20, 1996, XP002096565.	
JS	R55	LIN, Q., et al., "LIVER-SPECIFIC PROTEIN LISCH7", EMBL Sequence Database, November 1, 1996, XP002096566.	
	R56		

Examiner Signature	<i>[Signature]</i>	Date Considered	10/20/05
--------------------	--------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.